What was tested
Resmi Raju, Jeremie Oliver Piña, Aye Chan Myo, Parna Chattaraj, Taishi Komori, Mitsuaki Ono, Ziyi Wang, Didier Portilla and Rena N. D’Souza, from the Section on Craniofacial Genetic Disorders at NICHD, the Craniofacial Anomalies and Regeneration Section and the Molecular Biology of Bones and Teeth Section at NIDCR, Okayama University and the University of Virginia, asked where and when Wnt signaling acts when loss of Sclerostin domain-containing 1 causes extra teeth to form (DOI 10.1002/dvdy.70190). SOSTDC1 is the protein better known in this field as USAG-1, the target of the TRG-035 antibody in human trials, and its absence is known to enhance BMP and Wnt signaling and produce supernumerary teeth in mice, but competing hypotheses placed the initiating event at different sites and the responsible cell types were not resolved. The team compared developing maxillary incisors in Sostdc1 knockout and wild type mouse embryos across stages E15.5, E16.5 and E17.5, using spatial transcriptomic analysis validated by in situ mRNA hybridization of marker genes. The paper was published online on 6 October 2026 in Developmental Dynamics, the journal of the American Association of Anatomists, indexed as PMID 42836691.
What they found
In wild type embryos, Sostdc1 and Wnt10a showed inverse spatiotemporal expression in the developing maxillary incisor. In the knockout, the authors report ectopic expression of Wnt10a, Wnt6, Lrp4, Dkk1 and Sost, together with the appearance of a distinct subpopulation of mesenchymal cells whose marker profile pointed to an unexpected mix of osteogenic and odontogenic differentiation. This population first emerged at the rudimentary labial incisor outgrowth at about E15.5, expanded toward the lingual cervical loop at E16.5, and a separate supernumerary tooth formed at that lingual site by E17.5. The authors’ conclusion is that losing SOSTDC1-mediated inhibition of Wnt and BMP signaling produces aberrant mixed osteogenic and odontogenic differentiation of mesenchymal cells, which contributes first to the labial outgrowth and then to the lingual supernumerary tooth.
What it does not show
This report is grounded in the published abstract of record, not the full text, which sits behind a subscription wall that blocked automated retrieval, so we report the authors’ own abstract findings and no numbers beyond them: no sample sizes, no quantification, no detail on the spatial transcriptomics platform. Two boundaries matter for the field. First, the model is mouse embryology: these are Sostdc1 null embryos, not antibody-treated animals, so the paper maps the target’s biology, not the therapy’s pharmacology. Second, the causal claim is explicitly unproven: the authors themselves state that the direct functional role of the aberrant mesenchymal cells in supernumerary tooth formation remains to be established. The result is a spatiotemporal map and a hypothesis, not a mechanism demonstrated by rescue or loss-of-function experiments on the cell population itself.
Where it sits in the field
For the anti-USAG-1 antibody program, this is target-biology work from an independent NIH-led group, not the antibody’s originators: it sharpens the answer to where USAG-1 loss acts in the incisor, naming a lingual cervical loop mesenchyme as the site where the extra tooth actually forms, and it complicates the picture by showing the responding population is osteogenic as well as odontogenic. That mixed character is a caution for the therapeutic bet, since pharmacologic USAG-1 blockade aims to induce organized tooth formation, not aberrant mixed differentiation. The program’s tier stands unchanged at tier 4 on the sponsor’s completed Phase I single-ascending-dose study, with no peer-reviewed human results yet; today’s paper moves the mechanism map, not the clinical ledger. The current field assessment stands at /field/.
Where we differ from the coverage
We found no press or popular coverage of this paper to differ from. Against the abstract’s own framing, we hold back two inferences: “supernumerary tooth formation” here is a pathology of null-mutant embryos, and the jump from Sostdc1 knockout to what a partial, titrated USAG-1 antibody dose would do in a human jaw is the very gap the Phase II trials must close, so this paper should not be read as preclinical support for TRG-035 efficacy. We also note the direction of the Wnt10a finding: ectopic Wnt signaling marks the responding mesenchyme, but Dkk1 and Sost are themselves Wnt inhibitors, so the abstract describes a mixed signaling field, not a simple Wnt-on switch.
Provenance: grounded in the abstract of record, retrieved and cross-confirmed verbatim across PubMed (PMID 42836691), Europe PMC, Crossref and OpenAlex on 17 October 2026; the full text was not retrievable, so no claim beyond the abstract is made. Method and sourcing standard at /method/.